The post Vitalik Buterin Tightens Ethereum’s DeFi Standards appeared on BitcoinEthereumNews.com. Ethereum Foundation backs only permissionless, secure, open DeFiThe post Vitalik Buterin Tightens Ethereum’s DeFi Standards appeared on BitcoinEthereumNews.com. Ethereum Foundation backs only permissionless, secure, open DeFi

Vitalik Buterin Tightens Ethereum’s DeFi Standards

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
  • Ethereum Foundation backs only permissionless, secure, open DeFi protocols.
  • Buterin urges DeFi to remove admin keys and hidden controls to cut trust risks.
  • Buterin’s “walkaway test” says DeFi must run even if founders disappear.

Ethereum co-founder Vitalik Buterin said in a recent X post that the Ethereum Foundation has tightened its stance on decentralized finance and will not support every protocol that launches with a token and a dashboard.

Buterin sent a strong message to the DeFi space, i.e., to remove reliance on companies, admin keys, and hidden control points. If a system depends on a small group to pause, upgrade, or override it, that creates a trust risk. The Foundation does not want that risk embedded into Ethereum’s financial layer.

“Defi is a central part of the value that Ethereum provides,” Buterin said, adding that the Foundation will support projects that are permissionless, open-source, private, and provide security-first global finance. 

This statement comes as more institutional capital is entering Ethereum while banks and asset managers are exploring on-chain tools. If DeFi infrastructure keeps centralized choke points, Ethereum becomes traditional finance with new rails, while the Foundation wants the opposite.

The “Walkaway Test” Standard

Buterin introduced a hard filter, i.e., the “walkaway test.” If the founding team disappears, becomes hostile, or loses access, the protocol must continue to function. He said that there should be no emergency backdoors and no dependency on a multisig to survive.

Many DeFi systems still rely on admin keys or centralized infrastructure. These tools help manage risk in early stages, but they also create a single failure point.

Ethereum is permissionless, and anyone can deploy anything. However, the Foundation will not endorse systems that embed unnecessary centralized trust for convenience or short-term yield.

The intent is to minimize trusted third parties, centralized chokepoints, and maximize user control over assets.

Beyond “Better Stablecoins”

Buterin also challenged developers to move past incremental products. He pointed back to early DeFi innovation, such as automated market makers, which changed how markets function on-chain. That period focused on new financial primitives, not copies of existing bank products.

His criticism is aimed at shallow iterations. Building another stablecoin or yield wrapper is not enough. Buterin said that the focus should be on deeper problems like risk management, hedging future expenses, and global savings access without permission.

Related: Buterin Advances ETH Sale Plan, 70% Already Liquidated

Disclaimer: The information presented in this article is for informational and educational purposes only. The article does not constitute financial advice or advice of any kind. Coin Edition is not responsible for any losses incurred as a result of the utilization of content, products, or services mentioned. Readers are advised to exercise caution before taking any action related to the company.

Source: https://coinedition.com/vitalik-buterin-tightens-ethereums-defi-standards/

Market Opportunity
DeFi Logo
DeFi Price(DEFI)
$0.000355
$0.000355$0.000355
+11.63%
USD
DeFi (DEFI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09